Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.

Price Not Available 1 mg Abciximab Supplier Page
Trivial name Abciximab
Catalog Number TP-100CL
Alternative Name(s) Abciximab
Research Area Haemostasis and thrombosis
Molecular Formula C6462H9964N1690O2049S48
CAS# 143653-53-6
Purity >90%
Size 1 mg
Supplier Page
Additional Information Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting.